<DOC>
	<DOCNO>NCT00470535</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well erlotinib work treat patient stage III stage IV pancreatic cancer .</brief_summary>
	<brief_title>Erlotinib Treating Patients With Stage III Stage IV Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival ( PFS ) patient stage III IV adenocarcinoma pancreas treat erlotinib hydrochloride first- second-line therapy . Secondary - Determine proportion patient radiological response drug . - Determine overall survival patient . - Determine effect drug quality life patient . - Correlate expression EGFR , E-cadherin , P-cadherin , vimentin , cytokeratin , fibronectin , ki67 baseline tumor block presence K-ras mutation baseline tumor biopsy specimens response drug . - Correlate smoking status PFS patient treat drug . - Collect serum sample , , therapy future serum proteomic study development profile responder drug . OUTLINE : Patients receive oral erlotinib hydrochloride daily day 1-21 . Courses repeat every 21 day 12 month absence disease progression unacceptable toxicity . Patients complete questionnaire smoke status baseline . Patients also complete questionnaire quality life every three week study therapy completion study therapy . Blood sample collect patient baseline periodically study future serum proteomic research development profile responder erlotinib hydrochloride therapy . Paraffin-embedded tumor tissue diagnostic tumor biopsy assess baseline expression EGFR , E-cadherin , P-cadherin , vimentin , cytokeratin , fibronectin , ki67 immunohistochemical analysis . Tissue surgical specimen patient prior resection assess K-ras mutation K-ras analysis . After completion study therapy , patient follow least 6 month . PROJECTED ACCRUAL : A total 34 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas Locally advance inoperable metastatic disease ( stage III IV disease ) No 1 prior systemic therapy Patients receive 1 prior systemic therapy must meet 1 follow criterion : Ineligible refuse chemoradiotherapy AND stage III disease Ineligible refuse gemcitabine hydrochloridebased chemotherapy AND stage IV disease No brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month WBC &gt; 3,000/mm³ ANC &gt; 1,500/mm³ Platelet count &gt; 100,000/mm³ Bilirubin ≤ 2 mg/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 time ULN patient document liver metastasis ) Creatinine &lt; 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study therapy No uncontrolled comorbid illness likely increase toxicity study drug interfere toxicity evaluation No known allergy study drug excipients No symptomatic interstitial pulmonary disease PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior adjuvant therapy allow provide complete least 28 day prior study entry No prior EGFRinhibitor No concurrent drug know strong inducer inhibitor CYP450 enzyme system No concurrent Hypericum perforatum ( St. John 's wort ) No concurrent investigational commercial agent therapy intent treat patient 's malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>